Long-term oral antibiotic use in people with acne vulgaris in UK primary care: a drug utilization study

Author:

Bhate Ketaki1ORCID,Mansfield Kathryn E1,Sinnott Sarah-Jo1ORCID,Margolis David J2ORCID,Adesanya Elizabeth 1,Francis Nick3ORCID,Leyrat Clemence1ORCID,Hopkins Susan4ORCID,Stabler Richard5ORCID,Shallcross Laura6ORCID,Langan Sinéad M1ORCID,Mathur Rohini1ORCID

Affiliation:

1. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine , London , UK

2. Department of Dermatology and Department of Biostatistics and Epidemiology, University of Pennsylvania , Philadelphia, PA , USA

3. School of Primary Care, Population Sciences and Medical Education, University of Southampton , Southampton , UK

4. UK Health Security Agency , London , UK

5. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine , London , UK

6. Faculty of Population Health Sciences, University College London , London , UK

Abstract

Abstract Background The inappropriate use of antibiotics is understood to contribute to antimicrobial resistance. Oral antibiotics are regularly used to treat moderate-to-severe acne vulgaris. In practice, we do not know the typical length of oral antibiotic treatment courses for acne in routine primary care and what proportion of people receive more than one course of treatment following a new acne diagnosis. Objectives To describe how oral antibiotics are prescribed for acne over time in UK primary care. Methods We conducted a descriptive longitudinal drug utilization study using routinely collected primary care data from the Clinical Practice Research Datalink GOLD (2004–2019). We included individuals (8–50 years) with a new acne diagnosis recorded between 1 January 2004 and 31 July 2019. Results We identified 217 410 people with a new acne diagnosis. The median age was 17 years [interquartile range (IQR) 15–25] and median follow-up was 4.3 years (IQR 1.9–7.6). Among people with a new acne diagnosis, 96 703 (44.5%) received 248 560 prescriptions for long-term oral antibiotics during a median follow-up of 5.3 years (IQR 2.8–8.5). The median number of continuous courses of antibiotic therapy (≥ 28 days) per person was four (IQR 2–6). The majority (n = 59 010, 61.0%) of first oral antibiotic prescriptions in those with a recorded acne diagnosis were between the ages of 12 and 18. Most (n = 71 544, 74.0%) first courses for oral antibiotics were for between 28 and 90 days. The median duration of the first course of treatment was 56 days (IQR 50–93 days) and 18 127 (18.7%) of prescriptions of ≥ 28 days were for < 6 weeks. Among people who received a first course of oral antibiotic for ≥ 28 days, 56 261 (58.2%) received a second course after a treatment gap of ≥ 28 days. The median time between first and second courses was 135 days (IQR 67–302). The cumulative duration of exposure to oral antibiotics during follow-up was 255 days (8.5 months). Conclusions Further work is needed to understand the consequences of using antibiotics for shorter periods than recommended. Suboptimal treatment duration may result in reduced clinical effectiveness or repeated exposures, potentially contributing to antimicrobial resistance.

Funder

NIHR Doctoral Research Fellowship

Wellcome Trust

Health Data Research UK

UK Medical Research Council

Engineering and Physical Sciences Research Council

Economic and Social Research Council

Department of Health and Social Care

Health and Social Care Research and Development Division

Public Health Agency

British Heart Foundation

European Union Horizon 2020-funded BIOMAP Consortium

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3